WO2003063788A3 - PTPase INHIBITORS AND METHODS OF USING THE SAME - Google Patents

PTPase INHIBITORS AND METHODS OF USING THE SAME Download PDF

Info

Publication number
WO2003063788A3
WO2003063788A3 PCT/US2003/002770 US0302770W WO03063788A3 WO 2003063788 A3 WO2003063788 A3 WO 2003063788A3 US 0302770 W US0302770 W US 0302770W WO 03063788 A3 WO03063788 A3 WO 03063788A3
Authority
WO
WIPO (PCT)
Prior art keywords
ptpase
inhibitors
compounds
ptpase inhibitors
methods
Prior art date
Application number
PCT/US2003/002770
Other languages
French (fr)
Other versions
WO2003063788A2 (en
Inventor
Taolin Yi
Original Assignee
Cleveland Clinic Foundation
Taolin Yi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/238,007 external-priority patent/US7416723B2/en
Application filed by Cleveland Clinic Foundation, Taolin Yi filed Critical Cleveland Clinic Foundation
Priority to AU2003210741A priority Critical patent/AU2003210741A1/en
Publication of WO2003063788A2 publication Critical patent/WO2003063788A2/en
Publication of WO2003063788A3 publication Critical patent/WO2003063788A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to protein tyrosine phosphatase ('PTPase') inhibitors, and the use of PTPase inhibitors and PTPase inhibitors in combination with cytokines to treat diseases. Leishmaniasis agents have surprisingly and unexpectedly been found to be potent PTPase inhibitors. Examples of leishmaniasis agents that are also PTPase inhibitors include, but are not limited to, pentavalent antimonial compounds, imidazole compounds, and diamidine compounds. Therapeutic compositions and methods are provided that make use of these compounds to treat diseases.
PCT/US2003/002770 2002-01-30 2003-01-30 PTPase INHIBITORS AND METHODS OF USING THE SAME WO2003063788A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003210741A AU2003210741A1 (en) 2002-01-30 2003-01-30 Ptpase inhibitors and methods of using the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35301902P 2002-01-30 2002-01-30
US60/353,019 2002-01-30
US10/238,007 2002-09-09
US10/238,007 US7416723B2 (en) 2001-09-07 2002-09-09 Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases

Publications (2)

Publication Number Publication Date
WO2003063788A2 WO2003063788A2 (en) 2003-08-07
WO2003063788A3 true WO2003063788A3 (en) 2004-03-18

Family

ID=27668411

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/002770 WO2003063788A2 (en) 2002-01-30 2003-01-30 PTPase INHIBITORS AND METHODS OF USING THE SAME

Country Status (2)

Country Link
AU (1) AU2003210741A1 (en)
WO (1) WO2003063788A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215629A1 (en) * 2001-09-07 2005-09-29 Taolin Yi PTPase inhibitors and methods of using the same
US20070026398A1 (en) * 2003-03-03 2007-02-01 Farnsworth Amanda L Protein tyrosine phosphatase-prl-1 a a marker and therapeutic target for pancreatic cancer
WO2006000069A1 (en) * 2004-06-24 2006-01-05 Universidade Federal De Minas Gerais - Ufmg Pharmaceutical compositions consisting of cyclodextrin and an antimony derivative, their preparation as well as their use
NL1026931C2 (en) * 2004-08-31 2006-03-01 Friesland Brands Bv ACE-inhibiting whey hydrolysates.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859065A (en) * 1990-12-17 1999-01-12 University Of Manitoba Treatment method for cancer
US6143765A (en) * 1995-06-07 2000-11-07 Sugen, Inc. Pharmaceutical compositions and methods for modulating signal transduction

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859065A (en) * 1990-12-17 1999-01-12 University Of Manitoba Treatment method for cancer
US6143765A (en) * 1995-06-07 2000-11-07 Sugen, Inc. Pharmaceutical compositions and methods for modulating signal transduction

Also Published As

Publication number Publication date
WO2003063788A2 (en) 2003-08-07
AU2003210741A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
HK1149764A1 (en)
WO2002036562A3 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
WO2004071447A3 (en) Substituted azole derivatives as therapeutic agents
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
WO2003049702A8 (en) Vanilloid receptor ligands and their use in treatments
WO2002014311A3 (en) Urea compounds and methods of uses
WO2003024392A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003088808A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003000113A3 (en) Compositions and methods for the diagnosis and treatment of tumor
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
WO2004071448A3 (en) Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
MY144616A (en) Substituted dihydroquinazolines
WO2003018619A3 (en) Antimicrobial and anti-inflammatory peptides
GB0111186D0 (en) Novel compounds
DE60205455D1 (en) naphthyridine
WO2002051832A3 (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
WO2006110760A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2002007669A3 (en) Phospholipid derivatives of valproic acid and mixtures thereof
YU87202A (en) Arylmethylamine derivatives for use as tryptase inhibitors
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
AU2002233928A1 (en) Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP